PHARMACOKINETIC PROFILE OF TROGARZOTM PRESENTED AT IDWEEK Oct 03, 2018 PDF Version Supporting Materials: PHARMACOKINETIC PROFILE OF TROGARZOTM PRESENTED AT IDWEEK 245.3 KB Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that pharmacokinetic data from the pivotal phase III clinical trial for TrogarzoTM (ibalizumab-uiyk) injection will be presented tomorrow at IDWeekTM in San Francisco.